NAD+ vs. Peptide Therapy: Which Service Should Anchor Your Longevity Clinic Launch?

A Decision Framework for Entrepreneurs Choosing Their First Clinical Service in 2026

The Question Every New Longevity Clinic Owner Eventually Asks

Most entrepreneurs planning a longevity clinic eventually envision a full-service menu — NAD+ IV therapy, peptide protocols, hormone optimization, biomarker panels, all running together as a comprehensive practice. That vision is correct as an end state. It is the wrong place to start. A clinic that tries to launch all of these services simultaneously on day one spreads its clinical team, its supplier relationships, and its marketing budget across too many priorities to build genuine excellence in any single one during the critical first ninety days.

The practical question new clinic owners actually face is sequencing: which service earns the right to be the clinic's anchor while the rest of the menu builds out over the following months. For most longevity clinics, that decision comes down to NAD+ IV therapy versus peptide therapy. Both are high-demand, both attract the core longevity patient demographic, and both are covered in depth as complementary anchor services elsewhere on this blog. This post focuses specifically on the sequencing decision — which one to lead with when a clinic can only build deep operational excellence in one before expanding.

For the full longevity clinic business case and market data behind both services, see The Longevity Clinic Business Opportunity.

The Case for Leading with NAD+

NAD+ IV therapy has the lower operational complexity of the two services, which is the primary argument for launching with it first. Administration requires a licensed nurse with IV therapy experience — a skill set that is straightforward to hire for and train relative to the compounding pharmacy relationships and prescribing protocols that peptide therapy requires. There is no controlled substance framework to navigate, and the medical director's oversight role for NAD+ protocols is comparatively lighter than what peptide prescribing requires.

The market data supports NAD+ as a strong entry service. The global nicotinamide adenine dinucleotide market is projected to grow from approximately $3.9 billion in 2025 to $10.8 billion by 2035, a compound annual growth rate above 10 percent — reflecting the same consumer demand curve that is driving patients into longevity clinics specifically to ask about it.

NAD+ also has a lower commitment threshold for a first-time patient. A single infusion or short loading series is an accessible way for a new patient to experience the clinic's environment and clinical team without committing to a multi-month protocol relationship on their first visit. That accessible entry point makes NAD+ a strong choice for a clinic prioritizing patient volume and brand awareness in its first ninety days.

The Case for Leading with Peptide Therapy

Peptide therapy's advantage is different — it produces higher patient lifetime value once a patient is enrolled, because protocols run for months rather than a single session and are supported by monitoring data, primarily IGF-1 testing, that gives the clinical team a genuine ongoing reason to stay engaged with the patient. A Sermorelin or combination growth hormone secretagogue protocol generates recurring monthly revenue for six to twelve months or longer per patient, compared to NAD+'s pattern of a front-loaded series followed by lighter, less frequent maintenance sessions.

Peptide therapy also differentiates a new clinic more sharply in a competitive local market. NAD+ IV therapy has become widely available — many IV therapy lounges, med spas, and wellness centers now offer it as one of several drip options. Peptide therapy, particularly when built around a genuine clinical protocol with medical director oversight and IGF-1 monitoring, remains a more specialized offering that fewer competitors execute well. A clinic that leads with peptide therapy is making a bet on differentiation over accessibility.

The Operational Complexity Comparison

The clearest way to separate these two services is by what each requires operationally before the clinic can legally and safely offer it. NAD+ requires a licensed nurse or NP capable of IV administration, standard clinical supply infrastructure, and a medical director relationship providing prescribing oversight for the IV formulation — a comparatively contained compliance footprint.

Peptide therapy requires all of the above plus a working relationship with a licensed compounding pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, clinical protocol documentation specific to each compound the clinic intends to prescribe, and a medical director whose comfort and licensure explicitly covers peptide prescribing. None of this is prohibitive — ACG helps new clinics establish exactly this infrastructure as a standard part of the launch engagement — but it is measurably more setup work than NAD+ requires, which is the practical reason many clinics find it easier to have NAD+ fully operational before peptide therapy launches.

The Decision Framework for Most New Clinics

For the majority of new longevity clinic launches, the sequencing that produces the smoothest first ninety days is leading with NAD+ operationally while the compounding pharmacy relationship and peptide protocol documentation are finalized in parallel, then introducing peptide therapy in month two or three once the clinical team has found its rhythm with the first service. This is not a universal rule — it is the default that works for most markets and most first-time clinic owners.

The exception is a clinic whose target market skews heavily toward an athletic, recovery-focused, or performance-oriented patient demographic. In that specific market context, peptide therapy — particularly BPC-157 and growth hormone secretagogue protocols — often resonates more immediately than NAD+, and leading with it can make more sense despite the additional setup complexity. The right sequencing decision depends on genuine market and demographic analysis, not a one-size-fits-all rule, which is exactly the kind of decision ACG's market validation phase is built to inform before a clinic commits to its opening service menu.

To discuss the right sequencing for your specific market, visit altosconsultinggroup.com/survey.

Frequently Asked Questions

Can a longevity clinic launch with both NAD+ and peptide therapy from day one?

It is possible but not usually advisable for a first-time clinic owner. Building genuine clinical excellence, staff confidence, and patient trust in one service before adding a second produces a stronger first ninety days than splitting attention across two services simultaneously. Clinics with an experienced clinical team already in place, or those adding services to an existing practice rather than launching entirely from scratch, are better positioned to launch both together.

Which service has better margins, NAD+ or peptide therapy?

NAD+ typically has stronger margins on the initial loading series due to lower per-unit compound cost, while peptide therapy tends to produce better margins over the full patient relationship due to the recurring monthly revenue structure of protocol-based treatment. Neither is categorically more profitable — the answer depends on patient volume, retention rates, and how effectively the clinic converts initial patients into ongoing enrolled members.

Does the medical director requirement differ between the two services?

Both require medical director oversight, but the scope differs. NAD+ oversight covers IV formulation prescribing and administration protocols. Peptide therapy oversight must specifically cover the prescribing authority for each compound in the formulary, along with sign-off on protocol documentation and monitoring standards. A medical director comfortable with one is not automatically positioned to oversee the other without additional protocol development.

How long before I should add the second service after launching with the first?

Most clinics that lead with NAD+ are operationally ready to introduce peptide therapy within 60 to 90 days, once the compounding pharmacy relationship is established and protocol documentation has medical director sign-off. This timeline can run in parallel with the NAD+ launch rather than starting after it — the setup work for peptide therapy does not require NAD+ to be generating revenue first, it simply tends to take longer to complete, which is why NAD+ often goes live first even when both are being built simultaneously.